Biogen Inc.: New Data Presented at AD/PD 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein

Related Keywords

Gothenburg ,Vastra Gotalands Lan ,Sweden ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Priya Singhal ,Mike Hencke ,Jack Cox ,Youtube ,Twitter ,Alzheimer Association ,Nasdaq ,Exchange Commission ,Facebook ,International Conference On Alzheimer ,Linkedin ,Head Of Development At Biogen ,International Conference ,Executive Vice President ,Tau Protein ,Accessed March ,Tau Topic ,Accessed February ,Diese Gold Aktie ,Sichern Sie ,Biogen ,Data ,Resented ,023 ,Show ,Iib080 ,Apt ,Substantially ,Educed ,Protein ,Levels ,Patients ,Early ,Stage ,Lzheimer ,Disease ,